



LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 7, 2022

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- [LAVA Therapeutics N.V. \(Nasdaq: LVTX\)](#), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present in a virtual format at the H.C. Wainwright 24th Annual Global Investment Conference being held virtually and in New York City.

Presentation Details

Format: Virtual Corporate Presentation

Date: Monday, September 12, 2022

Time: Available for on-demand viewing at 7:00 a.m. EDT

A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at: <https://ir.lavatherapeutics.com/news-events/events>. A replay will be archived for 90 days following the presentation date.

About LAVA Therapeutics

LAVA Therapeutics N.V. is a clinical stage immuno-oncology company utilizing its proprietary Gammabody™ [platform](#) to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company's lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study ([NCT04887259](#)). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling (NCT05369000). For more information, please visit www.lavatherapeutics.com, and follow us on [LinkedIn](#), [Twitter](#) and [YouTube](#).

CONTACTS

Investor Relations

ir@lavatherapeutics.com

Argot Partners (IR/Media)

212-600-1902

lava@argotpartners.com